TriVascular Technologies (TRIV) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TriVascular Technologies, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
March 3, 2015 4:01 PM ESTSANTA ROSA, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq: TRIV), manufacturer of the Ovation Prime® Abdominal Stent Graft System, today reported financial results for the fourth quarter and year ended December 31, 2014.
Recent Accomplishments:
Fourth quarter revenue of $9.1 million, up 45.8% over the fourth quarter of 2013; Full year revenue of $31.8 million, growth of 63% compared to 2013 Â Fourth quarter gross margin of 63.5%, an increase from 52.3% in the fourth quarter of 2013 Â Received FDA and CE Mark approval of Ovation iX Iliac Limbs; commercial launch planned for the second half of 2015... More